$MACK News

Last published 2y ago

2y agoKRON MACK MXCT PHVS+4Vicore Expands and Strengthens its Board of DirectorsACCESS NewswireSTOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
2y agoMACKMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that
2y agoMACKMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder
2y agoMACKMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionBusiness WireCompany Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed
2y agoMACKMerrimack Receives $225 Million Milestone Payment from IpsenBusiness WireSpecial Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today
2y agoMACKMerrimack Reports Full Year 2023 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023. "As Ipsen reported in February, the U.S. Food
2y agoMACKMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Business WireFDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of
3y agoMACKMerrimack Reports Third Quarter 2023 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its third quarter 2023 financial results for the period ended September 30, 2023. "During the third quarter we saw
3y agoBNTX INCY MACK MRTX+1Pancreatic Cancer Battle Boosted by $200M VC FirmPR NewswireFN Media Group Presents USA News Group News Commentary
3y agoMACKMerrimack Reports First Quarter 2023 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its first quarter 2023 financial results for the period ended March 31, 2023. "During the first quarter of 2023 our
3y agoMACKMerrimack Reports Full Year 2022 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022. "We are encouraged by the results of the NAPOLI
3y agoMACKMerrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights PlanBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) (the "Company" or "Merrimack"), announced today that its Board of Directors (the "Board") has extended the Section 382 net operating loss rights plan (the "Plan") that was
3y agoAMGN MACK MRTX ONCY+1Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic CancerPR NewswireFN Media Group Presents USA News Group News Commentary VANCOUVER, BC, Nov. 15, 2022 /PRNewswire/ -- Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for
4y agoMACK MRK NRBO ONCY+1Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic CancerPR NewswirePALM BEACH, Fla., Nov. 10, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market competition, the market
4y agoMACKMerrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal AdenocarcinomaBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] announced that Ipsen, SA ("Ipsen") issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3
4y agoMACKMerrimack Reports Third Quarter 2022 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its third quarter 2022 financial results for the period ended September 30, 2022. "During the third quarter we continued to
4y agoMACKMerrimack Reports Second Quarter 2022 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its second quarter 2022 financial results for the period ended June 30, 2022. "We are pleased to report continued reductions in operating expenses as we re
4y agoMACKMerrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung CancerBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] announced that Ipsen, SA ("Ipsen") has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal inje
4y agoMACKMerrimack Reports First Quarter 2022 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its first quarter 2022 financial results for the period ended March 31, 2022. "During the first quarter of 2022 we continued to see reductions in our opera
4y agoMACKMerrimack Reports Full Year 2021 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2021 financial results for the period ended December 31, 2021. "During 2021 we have continued to reduce our operating expenses and remain focus
5y agoMACKMerrimack Reports Third Quarter 2021 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its third quarter 2021 financial results for the period ended September 30, 2021. "Both Ipsen Pharmaceuticals and Elevation Oncology publicly announced updat
5y agoMACKMerrimack Reports Second Quarter 2021 Financial ResultsBusiness WireMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its second quarter 2021 financial results for the period ended June 30, 2021. "We are pleased to report continued reductions in our operating expenses as wel
5y agoATNF MACK180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of DirectorsGlobeNewswireMENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory d
5y agoMACKMerrimack Reports Full Year 2020 Financial ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020.
5y agoMBRX IBIO MACK CATB+1Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid LeukemiaPR NewswireAcute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a...
6y agoMACKMerrimack Reports Third Quarter 2020 Financial ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020.
6y agoMACKMerrimack Reports Second Quarter 2020 Financial ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020.
6y agoMACKMerrimack Reports First Quarter 2020 Financial ResultsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020.
6y agoMACKMerrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy UpdateBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc. Merrimack will not receive any further contingent consideration or royalt ...
6y agoPFE MACKAlzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and PlanningBusiness WireFRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, announced today that Peter N. Laivins, MBA, has been appointed Head of Commercial Strategy and Planning. Mr. Laivins brings more than 20 years of leadership in the biopharmaceuti ...
6y agoMACKMerrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights PlanBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has adopted a Section 382 net operating loss rights plan (the “Plan”) and declared a dividend distribution of one Preferred Share Purchase Right on each outstanding share of Company common stock. The Plan is designed to protect ...
6y agoMACKMerrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special DividendBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomized portion of the trial focused on efficacy assessment. As a result of this mil ...
7y agoMACKMerrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special DividendBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today that the dividend amount for the previously authorized and declared $20 million special cash dividend (the “Special Dividend”) announced on July 25, 2019 is $1.496675 per outstanding share of Merrimack common stock. The dividend will be paid today, September 5, 2019, as previo ...
7y agoMACKMerrimack Pharmaceuticals Issues Letter to ShareholdersBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held on October 17, 2019.
7y agoMACKMerrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019. As a result, the record date for the 2019 Annual Meeting will now be September 16, 2019.
7y agoMACKMerrimack Declares $20 Million Special DividendPR NewswireMerrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 ...
9y agoMACKMerrimack Pharmaceuticals (MACK) CEO Richard Peters on Q2 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoHTGC WFC RBA AKAM+4Hercules Announces Second Quarter 2017 Financial Results and a $0.31 per Share Quarterly DistributionBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the second quarter ended June 30, 2017.
9y agoHTGC RBA AKAM MACK+3Hercules Capital Announces Additional Portfolio Company Liquidity Events and Congratulates Its Portfolio Companies on Their AchievementsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative, venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, is pleased to announce the latest liquidity events and achievements for the following portfolio companies:
9y agoMACKMerrimack Pharmaceuticals' (MACK) CEO Dr. Richard Peters on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
9y agoHTGC WFC RBA MACK+4Hercules Announces First Quarter 2017 Financial Results and a $0.31 per Share Quarterly DistributionBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the first quarter ended March 31, 2017.
9y agoHTGC MACK JAGX CERU+3Hercules Provides Interim Portfolio Update for Q1 2017Business WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE:HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today provided its interim portfolio update for the first quarter 2017.
9y agoHTGC WFC RBA EACQU+5Hercules Announces Fourth Quarter NII per Share of $0.43, Record Full-Year 2016 Financial Results and Quarterly Distribution of $0.31 per ShareBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE:HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the fourth quarter and fiscal-year ended December 31, 2016.
10y agoMACKMerrimack Pharmaceuticals' (MACK) CEO Gary Crocker On Q3 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoMACKMerrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoMACKMerrimack Pharmaceuticals' (MACK) CEO Robert Mulroy on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
11y agoBAX MACKBaxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic CancerBusiness WireDEERFIELD, Ill. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) jointly announced that Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of MM-398 (irinotecan liposome injection), also known as ''nal-IRI,'' an investigational treatment for patients with met ...
12y agoBAX MACKBaxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398Business WireDEERFIELD, Ill. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights ...
13y agoHTGC MACK INVE PATH+2Hercules Technology Growth Capital Announces Strong New Commitments in Quarter-to-Date Q4 2012 and Provides Year-to-Date 2012 Portfolio UpdateBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Technology Growth Capital, Inc. (NYSE: HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and cleantech industries, at all stages of development, today announced its quarter-to-date fourth quarter 2012 ...